James B. Yu

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

David C. Smith, N. Stambler, J. Sammon, 2014 .

Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists

C. Gross, R. Thompson, R. Karnes, 2014, Medical care.